Systemic neurokinin‐1 receptor antagonists mitigate chronic pruritus: A systematic review and meta‐analysis

医学 荟萃分析 速激肽受体1 受体 皮肤病科 药理学 内科学 P物质 神经肽
作者
Pei‐Yun Ho,Yu‐Chen Huang,Yi‐Tsz Lin
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:39 (10): 1738-1749 被引量:8
标识
DOI:10.1111/jdv.20807
摘要

BACKGROUND: Evidence suggests that substance P and neurokinin-1 receptor (NK1R) are often overexpressed in various chronic pruritus-inducing conditions. Several randomized controlled trials (RCTs) have demonstrated that targeting NK1R disrupts key itch signaling pathways, indicating the antipruritic effects of NK1R antagonists. However, these results remain to be validated. OBJECTIVES: In this systematic review and meta-analysis, we synthesized and evaluated clinical evidence on the efficacy of systemic NK1R antagonists against chronic pruritus. METHODS: PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched for relevant studies published from database inception to July 2024. We included RCTs and non-RCTs that compared NK1R antagonists with placebo and assessed reductions in patients' pruritus score. We further performed subgroup analyses by treatment duration, antagonist type, and disease type. RESULTS: This study included 13 RCTs,2 non-RCTs and 5 gray literatures (N = 2876 patients). Pooled data indicated that systemic NK1R antagonists significantly reduced chronic pruritus (standardized mean difference [SMD]: -0.448; 95% confidence interval [CI]: -0.735 to -0.161; p = 0.002) with a significant association in achieving a clinically meaningful 4-point improvement. (OR: 1.631; 95% CI: 1.251 to 2.127; p = 0.000). Across the studies, 33.9% of patients in the systemic NK1R antagonists group achieved a clinically meaningful 4-point improvement, compared to 24.7% in the placebo group. The reductions in patients' pruritus scores were significantly greater with serlopitant (SMD: -0.292; 95% CI: -0.513 to -0.072; p = 0.009) and aprepitant (SMD: -1.55; 95% CI: -2.967 to -0.132; p = 0.032) than with placebo. Furthermore, significant reductions were observed across nonmalignant dermatological conditions (SMD: -0.390; 95% CI: -0.669 to -0.111; p = 0.006). CONCLUSIONS: Our study suggests that systemic NK1R antagonists, particularly serlopitant and aprepitant, hold modest therapeutic effect for treating chronic pruritus, particularly in patients with nonmalignant dermatological conditions. Thus, clinicians can consider NK1R antagonists to effectively interrupt itch signaling in patients with chronic pruritus.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LIUJIAWEI完成签到,获得积分10
刚刚
刚刚
77完成签到,获得积分10
1秒前
jpl完成签到,获得积分10
1秒前
发论文完成签到,获得积分10
1秒前
茅草屋完成签到,获得积分10
1秒前
111发布了新的文献求助10
1秒前
1秒前
2秒前
脑洞疼的应助被yj采纳,获得10
2秒前
2秒前
2秒前
三井发布了新的文献求助10
2秒前
2秒前
3秒前
易宋发布了新的文献求助10
3秒前
彪壮的若男完成签到 ,获得积分10
3秒前
小二郎的应助被新帅采纳,获得10
3秒前
bkagyin的应助被smile采纳,获得10
3秒前
Breathe完成签到,获得积分10
3秒前
陈永伟完成签到,获得积分10
4秒前
发论文发布了新的文献求助20
4秒前
爱听歌谷蕊完成签到 ,获得积分10
4秒前
YAMP发布了新的文献求助50
5秒前
5秒前
热心的善愁完成签到,获得积分10
5秒前
奔跑的应助被羽七采纳,获得10
6秒前
深情安青的应助被科研采纳,获得10
6秒前
6秒前
烂漫乐曲完成签到 ,获得积分10
6秒前
haipronl发布了新的文献求助10
6秒前
王某某发布了新的文献求助10
6秒前
asdfghjkl完成签到,获得积分10
6秒前
7秒前
8秒前
核桃发布了新的文献求助10
8秒前
8秒前
8秒前
Hello的应助被阿白采纳,获得10
9秒前
小二郎的应助被阿白采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482